Mack Gene has filed 5 insider transactions across 1 company since April 2024.
Most recent transaction: a grant/award of 200000 shares of Gain Therapeutics, Inc. ($GANX) on March 24, 2026.
Activity breakdown: 1 open-market purchase and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 24, 2026 | Gain Therapeutics, Inc. | $GANX | Mack Gene | CEO, President | A | Employee Stock Option (right to buy) | 200000 | $0.00 | 200,000.0000 | 34,998,060 | 9999.99% | 0.57% |
| March 20, 2025 | Gain Therapeutics, Inc. | $GANX | Mack Gene | CEO, President | A | Employee Stock Option (right to buy) | 200000 | $0.00 | 200,000.0000 | 22,881,415 | 9999.99% | 0.87% |
| Jan. 6, 2025 | Gain Therapeutics, Inc. | $GANX | Mack Gene | CEO, President | A | Stock Option (right to buy) | 271325 | $0.00 | 271,325.0000 | 22,881,415 | 9999.99% | 1.19% |
| Aug. 9, 2024 | Gain Therapeutics, Inc. | $GANX | Mack Gene | CFO and Interim CEO | P | Common Stock | 14400 | $1.01 | 14,400.0000 | 19,215,582 | 9999.99% | 0.07% |
| April 8, 2024 | Gain Therapeutics, Inc. | $GANX | Mack Gene | Chief Financial Officer | A | Employee Stock Option (right to buy) | 200000 | $0.00 | 200,000.0000 | 17,978,951 | 9999.99% | 1.11% |